MAPK3 and type 2 diabetes mellitus: Furthermore, docking results verified our findings and showed that abrisapogenol J, abrusin, cycloartenol, and precatorine bind stably with the active pockets of target genes, which spotlight that these compounds can be considered for the treatment of T2DM by inhibiting AKT1, MAPK3, TNFalpha, and MAPK1 genes.